Clinical Trials Browser

Completed × Breast Neoplasms × trilaciclib × Clear all

NCT04799249 2024-08-01

PRESERVE 2

Phase 3 Completed

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Completed

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms